Public Data Commons

Provides measures of cardiovascular disease risk; coronary CT angiography; banking of immune cells, serum, plasma, and DNA; and longitudinal follow-up with imaging, risk markers, and cardiovascular events; in 500+ patients. Therapeutics targeting the immune response are currently the fastest growing class of drugs. However, the challenge of how we deliver targeted patient-specific approaches remains. Our goal with iPRIME is to reduce barriers for investigators to perform cutting-edge research on cardiovascular diseases by linking experts in Immunology, Imaging, and Informatics to drive Precision Medicine (iPRIME) forward at UVA. Since our inception and funding in 2022 we have built a cohort of over 1,100 patient samples to be used by approved researchers with the aims of discovering novel biomarkers of disease, using artificial intelligence to predict disease outcome, and determining personalized therapy response and risk. More information can be accessed here: https://iprime.virginia.edu The application to utilize biospecimens or clinical data can be accessed via the linked portal page below.